Skip to main content
JACK
NASDAQ Trade & Services

Activist Investor Biglari Capital Urges Vote Against Chairman, Poison Pill, and Executive Compensation

Analysis by Wiseek AI
Sentiment info
Negative
Importance info
9
Price
$21.59
Mkt Cap
$410.25M
52W Low
$13.993
52W High
$44.145
Market data snapshot near publication time

Summary

Activist investor Biglari Capital, holding nearly 10% of Jack in the Box, has filed a revised preliminary proxy statement urging shareholders to vote against the re-election of Chairman David Goebel and several key management proposals, citing years of underperformance and strategic missteps.


Key Events

  • Proxy Contest Intensifies

    Biglari Capital, with a 9.97% stake, is actively soliciting votes against Chairman David Goebel's re-election at the upcoming Annual Meeting on February 27, 2026.

  • Opposition to Key Proposals

    Biglari recommends voting 'AGAINST' the executive compensation (Say on Pay), an increase in shares for the 2023 Omnibus Incentive Plan, and the ratification of the 'poison pill' (Stockholder Protection Rights Agreement).

  • Cites Underperformance & Missteps

    The activist details the company's significant underperformance compared to peers and the Russell 3000, and criticizes the $460 million loss from the Del Taco acquisition as evidence of poor capital allocation.

  • History of Engagement Detailed

    The filing outlines Biglari's attempts to engage constructively with the Board, including seeking a board seat, which were ultimately rejected, leading to the proxy contest.


Analysis

This revised preliminary proxy statement from Biglari Capital Corp. intensifies the ongoing proxy contest by providing detailed arguments against the current leadership and corporate governance. Biglari, a significant shareholder with a nearly 10% stake, is actively campaigning for a vote against Chairman David Goebel, the company's 'Say on Pay' executive compensation proposal, an amendment to increase shares for the incentive plan, and the ratification of the 'poison pill' (Stockholder Protection Rights Agreement). The activist highlights the company's severe underperformance against peers and the Russell 3000 over multiple timeframes, as well as the substantial loss from the Del Taco acquisition. This represents a significant challenge to the incumbent board and management, potentially leading to substantial changes in leadership and corporate strategy if Biglari's campaign is successful.

At the time of this filing, JACK was trading at $21.59 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $410.3M. The 52-week trading range was $13.99 to $44.15. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

JACK - Latest Insights

JACK
May 13, 2026, 4:14 PM EDT
Filing Type: 10-Q
Importance Score:
8
JACK
May 13, 2026, 4:13 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
JACK
May 13, 2026, 4:12 PM EDT
Filing Type: 8-K
Importance Score:
8
JACK
Apr 13, 2026, 4:33 PM EDT
Filing Type: 8-K
Importance Score:
7
JACK
Mar 04, 2026, 1:32 PM EST
Filing Type: 8-K
Importance Score:
8
JACK
Feb 27, 2026, 1:35 PM EST
Source: Reuters
Importance Score:
9
JACK
Feb 26, 2026, 4:33 PM EST
Filing Type: DEFA14A
Importance Score:
7
JACK
Feb 24, 2026, 5:25 PM EST
Filing Type: DFRN14A
Importance Score:
8
JACK
Feb 23, 2026, 7:51 PM EST
Filing Type: DEFA14A
Importance Score:
8
JACK
Feb 20, 2026, 4:35 PM EST
Filing Type: DEFR14A
Importance Score:
8